Rybelsus 3 mg (Semaglutide) 10 Tablets
Rybelsus 3 mg (Semaglutide) is the world's first oral GLP-1 receptor agonist, offering the benefits of Ozempic in a pill.
Manufacturer: Novo Nordisk (India). This 3 mg pack represents Step 1 (Initiation). It contains 10 tablets per blister. This dose is strictly for dose escalation and acclimatization. It is not intended for effective glycemic control or significant weight loss yet.
Mechanism of Action ("Adaptation Phase"):
Rybelsus mimics the natural hormone GLP-1. The 3 mg dose gently introduces the drug to your system to mitigate gastrointestinal side effects before stepping up to the therapeutic doses of 7 mg and 14 mg.
✅ Goal: To prepare your body for higher doses without severe nausea.
Indicated for adults as a starting dose for:
- 🍬 Type 2 Diabetes Mellitus: To improve glycemic control (in combination with diet and exercise).
- ⚖️ Weight Management Preparation: Initiating therapy for long-term weight management protocols.
Packaging: 3 mg tablets (10 tablets per blister card).
⚠️ CRITICAL ADMINISTRATION INSTRUCTIONS:
- ⏰ Timing: Take on an empty stomach immediately upon waking up.
- 💧 Water: Swallow whole with a sip of plain water (max 120 ml / 4 oz). Do not use coffee, juice, or soda.
- ⏳ The Wait: Wait at least 30 minutes before eating, drinking, or taking other oral medications. Eating too soon will destroy the drug's absorption.
- 🗓️ Protocol: Take 3 mg daily for 30 days, then increase to 7 mg.
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pregnancy and breastfeeding (discontinue 2 months prior to conception).
- Pancreatitis history.
Common side effects during the first month (adaptation):
- 🤢 Gastrointestinal: Nausea is the most common adverse reaction. Diarrhea, vomiting, and decreased appetite may occur.
- 📉 Hypoglycemia: Risk increases when used with insulin or sulfonylureas.
Similar products
What Customers Say
No reviews yet
Your review can be the first!